Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma

Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma

Tumor Treating Fields (TTFields), an approved therapy for glioblastoma (GBM) and malignant mesothelioma, employ noninvasive application of low-intensity, intermediate-frequency, alternating electric fields to disrupt the mitotic spindle, leading to chromosome missegregation and apoptosis. Emerging e...

Full description

Bibliographic Details
Main Authors: Dongjiang Chen, Son B. Le, Tarun E. Hutchinson, Anda-Alexandra Calinescu, Mathew Sebastian, Dan Jin, Tianyi Liu, Ashley Ghiaseddin, Maryam Rahman, David D. Tran
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022-04-01
Series:The Journal of Clinical Investigation
Subjects:
Oncology
Online Access:https://doi.org/10.1172/JCI149258

Internet

https://doi.org/10.1172/JCI149258

Similar Items